Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Assets Average (2021 - 2025)

Krystal Biotech's Assets Average history spans 5 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 26.29% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $1.3 billion, up 26.29%, while the annual FY2025 figure was $1.2 billion, 27.5% up from the prior year.
  • Assets Average for Q4 2025 was $1.3 billion at Krystal Biotech, up from $1.2 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.3 billion in Q4 2025 and bottomed at $443.3 million in Q2 2021.
  • The 5-year median for Assets Average is $737.2 million (2023), against an average of $781.5 million.
  • The largest annual shift saw Assets Average fell 12.3% in 2023 before it skyrocketed 53.32% in 2024.
  • A 5-year view of Assets Average shows it stood at $538.7 million in 2021, then grew by 5.33% to $567.4 million in 2022, then skyrocketed by 41.76% to $804.4 million in 2023, then increased by 26.7% to $1.0 billion in 2024, then rose by 26.29% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Assets Average are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).